Stock Analiz

Inovio Pharmaceuticals, Inc. INO

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.43Market cap $268M
Open the interactive analysis →

Inovio Pharmaceuticals, Inc. (INO) is a healthcare company listed in the US with a market value of about $268M. In the twelve months to September 30, 2026 it had revenue of $298901 and net income of -$71M, a net margin of -23798.9%.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -61% a year, a 5-year average ROIC of -137%.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $10M in 2014 to $65343 in 2025, a decline of about 37.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 136% over three years (dilution for shareholders). It spends 82957% of revenue on research and development.

Score: 0.4 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S896.1
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-27.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-70.0%
Revenue growth (5 yrs, per year)-61.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-43066.1%
ROIC (5-yr avg.)-137.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$298901$65343$217756$832010$10M$2M$7M$4M$30M$42M$35M
Net income-$71M-$85M-$107M-$135M-$280M-$304M-$166M-$119M-$97M-$88M-$74M
Free cash flow-$74M-$89M-$105M-$125M-$217M-$217M-$179M-$99M-$76M-$74M-$65M
EPS (diluted)$-0.59$-0.45$-0.99$-1.52$-3.52$-4.36$-3.21$-3.63$-3.15$-3.27$-3.03
Net margin-23798.9%-130000.0%-49254.3%-16239.9%-2726.7%-17109.9%-2245.4%-2902.8%-318.1%-208.9%-208.5%
ROIC—-259.4%-139.8%-110.1%-105.2%-72.1%-25.8%-427.8%-67.9%-58.7%-61.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $6.33, 343% above the current price; targets range from $5.00 to $8.00; the consensus rating is “Strong buy”; expected EPS is $-0.90 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Inovio Pharmaceuticals pay a dividend?

Not currently.

Is Inovio Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Inovio Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.